Cellectar Biosciences, Inc. (CLRB)
1.25
+0.10
(+8.70%)
USD |
NASDAQ |
Nov 06, 16:00
1.24
-0.01
(-0.80%)
After-Hours: 20:00
Cellectar Biosciences Net Income (Quarterly) : -6.931M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -6.931M |
| March 31, 2026 | -5.654M |
| December 31, 2025 | -5.295M |
| September 30, 2025 | -4.444M |
| June 30, 2025 | -5.448M |
| March 31, 2025 | -6.604M |
| December 31, 2024 | -2.355M |
| September 30, 2024 | -14.66M |
| June 30, 2024 | -0.9194M |
| March 31, 2024 | -26.64M |
| December 31, 2023 | -7.881M |
| September 30, 2023 | -17.52M |
| June 30, 2023 | -10.18M |
| March 31, 2023 | -7.190M |
| December 31, 2022 | -12.41M |
| September 30, 2022 | -7.811M |
| June 30, 2022 | -7.435M |
| March 31, 2022 | -6.140M |
| December 31, 2021 | -5.918M |
| September 30, 2021 | -5.819M |
| June 30, 2021 | -6.028M |
| March 31, 2021 | -6.357M |
| December 31, 2020 | -3.615M |
| September 30, 2020 | -3.910M |
| June 30, 2020 | -3.612M |
| Date | Value |
|---|---|
| March 31, 2020 | -3.958M |
| December 31, 2019 | -3.380M |
| September 30, 2019 | -3.904M |
| June 30, 2019 | -3.188M |
| March 31, 2019 | -3.622M |
| December 31, 2018 | -3.828M |
| September 30, 2018 | -3.015M |
| June 30, 2018 | -2.921M |
| March 31, 2018 | -3.476M |
| December 31, 2017 | -4.079M |
| September 30, 2017 | -3.471M |
| June 30, 2017 | -3.122M |
| March 31, 2017 | -2.891M |
| December 31, 2016 | -2.585M |
| September 30, 2016 | -2.287M |
| June 30, 2016 | -2.133M |
| March 31, 2016 | 0.8246M |
| December 31, 2015 | 0.9509M |
| September 30, 2015 | -1.858M |
| June 30, 2015 | -2.287M |
| March 31, 2015 | -2.301M |
| December 31, 2014 | -2.571M |
| September 30, 2014 | 0.324M |
| June 30, 2014 | -2.086M |
| March 31, 2014 | -2.943M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 53.52M |
| Alnylam Pharmaceuticals, Inc. | 2.167B |
| Anika Therapeutics, Inc. | -0.311M |
| Savara, Inc. | -40.23M |
| Vericel Corp. | 14.16M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 6.931M |
| EPS Diluted (Quarterly) | -0.5666 |
| Enterprise Value | -22.15M |
| Earnings Yield | -364.3% |
| Normalized Earnings Yield | -375.10 |